Lilly's Zepbound Beats Novo's Wegovy in Head-to-Head Trial.

In a recent head-to-head trial, Eli Lilly & Co.'s weight-loss drug Zepbound was found to be more effective than Novo Nordisk A/S's Wegovy, with Zepbound users losing an average of 20% of their body weight over 72 weeks compared to 14% for Wegovy users. The results present an opportunity for Lilly to compete in the growing pharmaceutical market, which is expected to reach $130 billion by the end of the decade. Both drugs had similar gastrointestinal-related side effects, and further research is being conducted to explore additional benefits and improvements in weight loss treatments. [Extracted from the article]